Predictive value of radiomic signature based on 2-[18F]FDG PET/CT in HER2 status determination for primary breast cancer with equivocal IHC results-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Predictive value of radiomic signature based on 2-[18F]FDG PET/CT in HER2 status determination for primary breast cancer with equivocal IHC results

Published:2023-10 Issue: Volume:167 Page:111050
ISSN:0720-048X
Container-title:European Journal of Radiology
language:en
Short-container-title:European Journal of Radiology

Author:

Liu Jianjing,Zhang Zhanlei,Bian Haiman,Zhang Yufan,Ma Wenjuan,Wang Ziyang,Yin Guotao,Dai Dong,Chen Wei,Zhu Lei,Xu Wengui,Zhang Hong,Li Xiaofeng

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference40 articles.

1. Cancer Statistics, 2021;Siegel;CA A Cancer J. Clin.,2021

2. Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review;Verschoor;Cancer Treat. Rev.,2022

3. A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer;Subramaniyan;Chemico-Biol. Interact.,2022

4. N. Ishiyama, M. O'Connor, A. Salomatov, D. Romashko, S. Thakur, A. Mentes, J.F. Hopkins, G.M. Frampton, L.A. Albacker, A. Kohlmann, C. Roberts, E. Buck E, Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects, Cancer Res. (2022) canres.0940.2021.

5. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Breast Imaging of HER2-Positive Breast Cancer in the Era of PHERGain Trial: The past, the Present, and the Prospects;Cancer Biotherapy and Radiopharmaceuticals;2024-08-01

2. Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response;Journal of Clinical Medicine;2023-12-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3